COMING IN OCTOBER FROM

The Outcomes Creativity Index (OCI) is a ranking of pharmaceutical companies and brands according to creativity and innovation.

The OCI is an aggregate score-based creative achievement representing these U.S. and International award shows: The Outcomes LLC/ Med Ad News Manny Awards, Cannes Lions, LIA: Health and Wellness, Clio Health, The One Show: 58 Health, Wellness & Pharma, The MM&M Awards, OUTCOMES CREATIVITY INDEX The Global Awards, and The Creative Floor Awards. Every year, Med Ad News recognizes the MANNY AWARDS — 7 CANNES LIONS — 15 top ten pharma companies and top ten brands LIA: HEALTH & WELLNESS — 7 according to their ranking in the October edition CLIO HEALTH — 7 of Med Ad News, which includes a Q&A with the THE ONE SHOW: HW&P — 7 number one company’s CMO and number one THE MM&M AWARDS — 4 brand’s marketing team. THE GLOBAL AWARDS — 7 THE CREATIVE FLOOR AWARDS — 4

top 50 pharma companies

Johnson & Johnson One Johnson & Johnson Plaza, ew runswick, J 09 58 OUTCOMES CREATIVITY INDEX Telephone: 2-2-000 Website: n.com MANNY AWARDS — 7 CANNES LION — 15 LIA: HEALTH & WELLNESS — 7 CLIO HEALTH — 7 THE ONE SHOW: HW&P — 7 THE MM&M AWARDS — 4 THE GLOBAL AWARDS — 7 De ning the THE CREATIVE FLOOR AWARDS — 4

future of healthcare BEST SELLING RX PRODUCTS 2017 2016 PRODUCT SALES SALES The eecutive management team of this 12-year-old Remicade ,1 ,9 startup company is ecited about a future that lies beyond Stelara ,011 ,22 Invega Sustenna/ 2,9 2,21 the intersection of science and technology. eplion, Invega Trinza/ Time Period: Invega Trevicta ytiga 2,0 2,20 hroughout the de- phrenia), Oncology (e.g., prostate arelto 2,00 2,2 cades, Johnson & cancer and hematologic malig- Imbruvica 1,9 1,21 Johnson has ad- nancies), Cardiovascular and Simponi, 1, 1, August 2019 Creative Floor Awards T Simponi Aria vanced with the evo- Metabolism (e.g., thrombosis and Prezista, 1,21 1,1 lution of science and technology diabetes) and Pulmonary Hyper- Prezcobi/Rezolsta, – whether via the company’s pi- tension (e.g., Pulmonary Arterial Symtuza oneering development of sterile Hypertension). The latter is a arzale 1,22 2 to June 2020 Manny Awards surgery at the turn of the 20th new therapeutic area that was es- elcade 1,11 1,22 Invokana, 1,111 1,0 century – or today as 134,000 tablished with the acquisition of Invokamet employees work together to in June 2017. The Med- Procrit/Epre 92 1,10 develop a diff erentiated robot- ical Devices segment consists of a Risperdal Consta 0 9 ic-assisted surgery platform in broad range of products used in “Our strong second-quarter (2018) results reflect double- Concerta/ 91 orthopaedics, build novel regi- the orthopaedic, surgery, cardio- digit growth in our Pharmaceutical business and the Edurant/ 1 mens to boost T cells and train vascular, diabetes care and eye accelerating sales momentum in our Medical Devices Opsumit them to recognize and attack health fi elds. The Consumer seg- business, driven by the continued growth of our market All sales are in millions of dollars. Results: cancer through groundbreaking ment encompasses a wide array immuno-oncology eff orts, and of products used in the baby care, leading products and strategic new launches. We remain focused on investing in innovation and meeting the needs FINANCIAL PERFORMANCE focus to create the fi rst vaccine oral care, beauty, over-the-count- 2017 2016 for HIV/AIDS. Management er pharmaceutical, women’s of our customers by delivering innovative products and Revenue ,0 1,90 says these are just some of the health and wound-care markets. solutions that position the company to deliver long-term, et income 1,00 1,0 The scoring system is based on many examples that underscore “Our Pharmaceutical business sustainable growth. Our talented J&J colleagues are united iluted EPS 0. .9 J&J’s commitment to lead the has delivered outstanding and in our efforts to address some of the most critical health and R& epense 10, 9,09 next frontier of health. sustained performance for more consumer needs of people around the world.” 1H 2018 1H 2017 With more than 260 operating than seven years, driven by the Chairman & CEO Alex Gorsky Revenue 0,9 ,0 aggregate points for the measurement companies worldwide, execu- successful launch and growth of et income ,21 ,29 tives describe J&J as the world’s many blockbuster medicines,” iluted EPS .0 .00 R& epense ,0 , largest and most broadly based states J&J Chairman and CEO healthcare company. J&J is or- Alex Gorsky. “As we move for- ing investment in innovation is quartered Legend Biotech to All gures are in millions of dollars, except EPS. period by brand and by company. A top ganized into three business seg- ward, we will drive the contin- the most important aspect of develop a breakthrough in- ments: Pharmaceutical, Medical ued growth of our existing med- J&J’s strategy. During 2017, the vestigational CAR-T cell im- Devices, and Consumer. icines, while also delivering on company attained record levels munotherapy against multiple The Pharmaceutical segment is our near-term pipeline. And, we of investment: $10.6 billion in myeloma. “We are hopeful that last three-, fi ve-, ten- and twen- ten list for the brands and top ten list for concentrated on six therapeutic remain focused on driving ro- R&D and $35.2 billion in M&A. by applying shared knowledge ty-year periods,” Gorsky says. areas: Immunology (e.g., rheu- bust innovation to address high This resulted in various and new and expertise, we can create “Our shareholder return for 2017 matoid arthritis, infl ammatory unmet medical needs and lever- collaborations, including Acte- regimens that aim for a cure,” is indicative of the strength of our bowel disease and psoriasis), In- aging our strong commercial ca- lion – J&J’s largest-ever acqui- Gorsky explains. business, as well as the long-term fectious Diseases and Vaccines pabilities across each of our six sition – which added the sixth According to Gorsky, “We will strategic focus and execution that the companies is published annually in (e.g., HIV/AIDS), Neuroscience therapeutic areas.” therapeutic area to the compa- invest as much as possible in inno- our leaders and teams have deliv- (e.g., mood disorders and schizo- According to Gorsky, increas- ny’s Pharmaceutical business. vation and the R&D of new solu- ered over the past several years.” “Adding Actelion’s portfolio to tions and new products. Johnson our already strong Pharmaceu- & Johnson ranks among the top PERFORMANCE & OUTLOOK the Med Ad News October edition. The tical business has created a dis- fi ve companies in the U.S. across tinct opportunity for Johnson all industries for investment orldwide sales for John- & Johnson by expanding our in R&D — demonstrating our Wson & Johnson during portfolio with leading, diff er- commitment to driving growth fi rst-half 2018 totaled $40.84 Med Ad News team will interview the #1 entiated in-market medicines, through innovation across all billion, representing 11.6 growth cutting-edge new therapies and operations. We strongly believe over same-time 2017, including promising late-stage products,” this is the best way to stimulate operational growth of 8.6 per- Gorsky notes. economic growth throughout our cent. According to J&J, currency brand marketing team and the CMO for “Additionally, adding Abbott industry, company, and commu- fl uctuations had a positive im- Medical Optics to our portfolio nities. Most importantly, we be- pact of 3 percent for 2018’s fi rst allows us to expand into new ar- lieve that increased and focused six months. The net impact of eas within the eye health space. investment in innovation and acquisitions and divestitures on In total, we completed 17 ac- R&D is the best way to ultimately global operational sales growth the #1 company for publication in the quisitions and licensing agree- benefi t and positively impact our was a positive 3.3 percent. ments of various sizes, 60 inno- patients, consumers and share- Sales by J&J U.S. companies vation deals and made 21 new holders around the world. in January-June 2018 amount- investments through Johnson “Johnson & Johnson’s total ed to $20.59 billion, up 7.8 per- October magazine. The blockbuster brand Stelara is marketed for treating various immune- & Johnson Innovation – JJDC shareholder return for 2017 was cent versus the 2017 fi rst half. mediated inflammatory diseases. J&J’s immunology products achieved Inc. during 2017,” Gorsky says. more than 24%, exceeding our International sales were report- operational growth of 11.5 percent during first-half 2018 compared to J&J remains a preferred part- competitor composite, as well ed at $20.25 billion, rising 15.7 the same period one year earlier, driven by strong uptake of the biologic ner in collaborative innovation. as exceeding most major indices percent over the 2017 corre- Stelara in Crohn’s disease. In late 2017, J&J announced a which, I am proud to say, John- sponding period, including op- collaboration with China-head- son & Johnson has done over the erational growth of 9.3 percent

digital edition available at medadnews.com MedAdNews APRIL 2019 • 27